Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses the diagnosis and prognosis of patients with locally advanced cutaneous squamous cell carcinoma.
1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have a median progression-free survival and overall survival of 22.5 months. Evidence Rating Level: 2 (Good) Study Rundown: Solid organ transplant recipients receiving chronic immunosuppression have an increased risk of cutaneous squamous cell carcinoma (CSCC). Cemiplimab,
Edgardo Santos, MD, FACP, FCCP, offers expert insights into the squamous subgroup analysis of EMPOWER-Lung1 and 3, shedding light on the implications of these data for the treatment of individuals with squamous non-small cell lung cancer (NSCLC).
Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.
Neil D. Gross, MD, FACS, discusses how treatment with neoadjuvant cemiplimab followed by surgery with curative intent prolonged event-free survival in patients with stage II to IV cutaneous squamous cell carcinoma, adding that these outcomes warrant further investigation in a randomized setting.